Patients with wet age-related macular degeneration (Wet AMD) should be eligible for 14 lucentis (ranibizumab) injections per eye, says the National Institute for Health and Clinical Excellence (NICE). This is a complete reversal on its previous recommendation. The new recommendation does not include eligibility for Macugen, another injection. [click link for full article]

More: continued here

This entry was posted on Saturday, December 15th, 2007 at 9:12 am and is filed under Eye Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.